Focused On-demand Library for Dimethyladenosine transferase 1, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8WVM0

UPID:

TFB1M_HUMAN

Alternative names:

Mitochondrial 12S rRNA dimethylase 1; Mitochondrial transcription factor B1; S-adenosylmethionine-6-N', N'-adenosyl(rRNA) dimethyltransferase 1

Alternative UPACC:

Q8WVM0; Q05DR0; Q9Y384

Background:

Dimethyladenosine transferase 1, mitochondrial, also known as mitochondrial 12S rRNA dimethylase 1, plays a crucial role in mitochondrial function. It is a S-adenosyl-L-methionine-dependent methyltransferase, specifically targeting mitochondrial 12S rRNA. This enzyme is vital for the basal transcription of mitochondrial DNA, interacting with POLRMT and TFAM to stimulate transcription beyond its methyltransferase activity.

Therapeutic significance:

Understanding the role of Dimethyladenosine transferase 1, mitochondrial could open doors to potential therapeutic strategies. Its critical function in mitochondrial DNA transcription and rRNA modification underscores its potential as a target for therapeutic intervention in diseases linked to mitochondrial dysfunction.